The exact mechanism responsible for infusion-related reactions (IRRs) after monoclonal antibody (mAb) therapy is unclear. It is also unknown before treatment which patient will develop IRRs. The ...
On March 22, the U.S. Food and Drug Administration, or FDA, issued an emergency use authorization for Pemgarda — a new drug that prevents COVID-19 infection — for certain adults and adolescents, ...
We included 692 patients, of whom 6.7% (n = 47) had experienced one or more IRRs (n = 63). The highest incidence of IRRs (n = 50) were found in patients treated with rituximab (incidence IRR 26%), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results